Compare GAIN & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAIN | DRTS |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | Israel |
| Employees | 70 | 121 |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.5M | 641.6M |
| IPO Year | N/A | N/A |
| Metric | GAIN | DRTS |
|---|---|---|
| Price | $15.91 | $10.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $14.75 | $8.67 |
| AVG Volume (30 Days) | 420.2K | ★ 816.8K |
| Earning Date | 05-12-2026 | 05-18-2026 |
| Dividend Yield | ★ 9.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.07 | N/A |
| Revenue Next Year | $7.32 | $699.98 |
| P/E Ratio | $4.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.14 | $2.81 |
| 52 Week High | $17.14 | $11.62 |
| Indicator | GAIN | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 58.03 |
| Support Level | $15.78 | $6.59 |
| Resistance Level | $17.04 | N/A |
| Average True Range (ATR) | 0.63 | 0.89 |
| MACD | -0.13 | 0.13 |
| Stochastic Oscillator | 51.29 | 64.26 |
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.